DeLong Mark Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 23, 2026
Research Summary
AI-generated summary of this filing
Apellis (APLS) Chief Business & Strategy Officer Mark DeLong Sells 3,371 Shares
What Happened
Mark Jeffrey DeLong, Chief Business & Strategy Officer at Apellis Pharmaceuticals (APLS), sold 3,371 shares on January 22, 2026, at $21.77 per share, for proceeds of $73,371. The filing (Form 4) reports the sale as an open market or private sale and is coded as a sale (S). This transaction was executed to cover tax withholding on Restricted Stock Units (RSUs) that vested on January 21, 2026, per the filing footnote.
Key Details
- Transaction date: 2026-01-22; price: $21.77 per share; total proceeds: $73,371.
- Report filed: 2026-01-23 (timely relative to the transaction date).
- Shares owned after the transaction: not specified in this filing.
- Footnote: sale was to satisfy tax withholding on RSUs released January 21, 2026. (Footnote F1)
- Transaction type: Sale (S); reported as open market or private sale.
Context
Sales to cover tax withholding on vested RSUs are routine compensation-related transactions and do not necessarily signal the insider's view on company prospects. Purchases generally carry more weight for assessing insider sentiment; this filing documents a routine, tax-related disposition.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-01-22$21.77/sh−3,371$73,371→ 78,353 total
Footnotes (1)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 21, 2026.